FR2407716A1 - Preparation pharmaceutique a base d'acide benzoique ou de ses sels pour diminuer la formation et l'elimination d'oxalate dans les urines et son utilisation - Google Patents

Preparation pharmaceutique a base d'acide benzoique ou de ses sels pour diminuer la formation et l'elimination d'oxalate dans les urines et son utilisation

Info

Publication number
FR2407716A1
FR2407716A1 FR7831222A FR7831222A FR2407716A1 FR 2407716 A1 FR2407716 A1 FR 2407716A1 FR 7831222 A FR7831222 A FR 7831222A FR 7831222 A FR7831222 A FR 7831222A FR 2407716 A1 FR2407716 A1 FR 2407716A1
Authority
FR
France
Prior art keywords
formation
oxalate
urine
salts
benzoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7831222A
Other languages
English (en)
Other versions
FR2407716B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Madaus Holding GmbH
Original Assignee
Dr Madaus GmbH and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Madaus GmbH and Co filed Critical Dr Madaus GmbH and Co
Publication of FR2407716A1 publication Critical patent/FR2407716A1/fr
Application granted granted Critical
Publication of FR2407716B1 publication Critical patent/FR2407716B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'INVENTION CONCERNE UNE COMPOSITION PHARMACEUTIQUE POUR DIMINUER LA FORMATION DES CALCULS URINAIRES. ON UTILISE UNE DOSE DE 400 A 1000MG POUR 24HEURES D'ACIDE BENZOIQUE OU DES QUANTITES EQUIVALENTES DE SES SELS, EVENTUELLEMENT EN PRESENCE DE RETINOL, DE THIAMINE, DE PYRIDOXINE, DE FOLATE ETOU D'ACIDE PANTHOTENIQUE. ON DIMINUE LA FORMATION DE DEPOTS D'OXALATE PAR TRANSFORMATION INTERMEDIAIRE DE L'OXALATE ENDOGENE EN D'AUTRES CONSTITUANTS ELIMINABLES SIMPLEMENT DANS LES URINES.
FR7831222A 1977-11-05 1978-11-03 Preparation pharmaceutique a base d'acide benzoique ou de ses sels pour diminuer la formation et l'elimination d'oxalate dans les urines et son utilisation Granted FR2407716A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2749618A DE2749618C3 (de) 1977-11-05 1977-11-05 Verhinderung der endogenen Oxalat-Harnsteinbildung

Publications (2)

Publication Number Publication Date
FR2407716A1 true FR2407716A1 (fr) 1979-06-01
FR2407716B1 FR2407716B1 (fr) 1981-07-31

Family

ID=6023126

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7831222A Granted FR2407716A1 (fr) 1977-11-05 1978-11-03 Preparation pharmaceutique a base d'acide benzoique ou de ses sels pour diminuer la formation et l'elimination d'oxalate dans les urines et son utilisation

Country Status (13)

Country Link
US (1) US4439449A (fr)
JP (1) JPS5476829A (fr)
BE (1) BE871808A (fr)
CH (1) CH648208A5 (fr)
DE (1) DE2749618C3 (fr)
DK (1) DK492178A (fr)
ES (1) ES474808A1 (fr)
FR (1) FR2407716A1 (fr)
GB (1) GB2007093B (fr)
IT (1) IT1100909B (fr)
LU (1) LU80468A1 (fr)
NL (1) NL7810914A (fr)
SE (1) SE7811312L (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046580A1 (de) * 1980-12-11 1982-07-01 Leskovar, Peter, Dr.-Ing., 8000 München Harnsteinaufloesende mittel
DE3441502A1 (de) * 1984-11-14 1986-05-15 Farco-Pharma GmbH, 5000 Köln Pharmazeutisches praeparat zur prophylaxe von kalziumoxalatsteinen
US5285795A (en) * 1991-09-12 1994-02-15 Surgical Dynamics, Inc. Percutaneous discectomy system having a bendable discectomy probe and a steerable cannula

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164524A (en) * 1961-02-27 1965-01-05 Warner Lambert Pharmaceutical Oral antiseptic

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CA1972 *

Also Published As

Publication number Publication date
US4439449A (en) 1984-03-27
NL7810914A (nl) 1979-05-08
FR2407716B1 (fr) 1981-07-31
LU80468A1 (de) 1979-03-19
IT7829429A0 (it) 1978-11-03
CH648208A5 (de) 1985-03-15
DK492178A (da) 1979-05-06
ES474808A1 (es) 1979-10-16
GB2007093B (en) 1982-05-12
BE871808A (fr) 1979-05-07
DE2749618C3 (de) 1984-12-20
SE7811312L (sv) 1979-05-06
DE2749618B2 (de) 1981-08-13
GB2007093A (en) 1979-05-16
IT1100909B (it) 1985-09-28
DE2749618A1 (de) 1979-05-10
JPS5476829A (en) 1979-06-19

Similar Documents

Publication Publication Date Title
Weil-Malherbe et al. Blood-brain barrier for adrenaline
Price et al. New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease.
DE10199022I1 (de) Omeprazol-Salze
FR2441609A1 (fr) Nouveau l-gamma-glutamyl-3-carboxy-4-hydroxyanilide et ses sels et leur application a la determination de l'activite de g-glutamyl-transpeptidase
Meinhold et al. Radioimmunoassay of 3, 3′, 5′-triiodo-L-thyronine (reverse T3) in human serum and its application in different thyroid states
ES431736A1 (es) Procedimiento para la preparacion de un agente para diagnos-tico para el proposito de efectuar el control de la capaci- dad de coagulacion de la sangre.
HEFFNER et al. Electrophoretic analyses of secreted human endometrial proteins: identification and characterization of luteal phase prolactin
ATE111879T1 (de) Wässrige bor enthaltende zusammensetzungen.
FR2407716A1 (fr) Preparation pharmaceutique a base d'acide benzoique ou de ses sels pour diminuer la formation et l'elimination d'oxalate dans les urines et son utilisation
Weinstein et al. THE PLASMA VITAMIN B 12 BINDING SUBSTANCE: I. ITS DETECTION IN THE SEROMUCOID FRACTION OF PLASMA FROM NORMAL SUBJECTS AND PATIENTS WITH CHRONIC MYELO-CYTIC LEUKEMIA
Ohta et al. Conformational change of tyrosyl-RNA synthetase induced by its specific transfer RNA
SE8405588D0 (sv) New compounds
JPH0921804A (ja) イムノアッセイ用のトロポニンの安定組成物およびそのような安定組成物の製法
Kamm et al. The effects of acidosis and alkalosis on the metabolism of glutamine and glutamate in renal cortex slices
ATE33620T1 (de) Wasserloesliche zusammensetzungen zur herstellung analytischer loesungen.
GB1263756A (en) Radioactively labelled phenylalkyl carboxylic compounds and their use in determining fat absorption
Eyring et al. Interaction of gold and penicillamine
ATE47518T1 (de) Injizierbare pharmazeutische zusammenstellungen die bestaendige 5-adenosyl-l-methionin-salze enthalten.
Knott et al. Therapeutic drug monitoring in pregnancy rationale and current status
GB1294518A (en) Test kit for use in the determination of uric acid in blood serum
Zuspan et al. Identification of a pressor substance in amniotic fluid: I. Role of epinephrine and norepinephrine
GB1424427A (en) Determination of calcium
ES2033834T3 (es) Un metodo para determinar alteraciones de la gestion.
Baumgarten et al. 4-Aninomethylbicyclo [2.2. 2]-Octane-1-Carboxylic Acid a New Potent Antifibrinolytic Agent
Harnach The analysis of calcium in unashed saliva

Legal Events

Date Code Title Description
ST Notification of lapse